Datasheet for ABIN730010

anti-GLP-1 antibody (AA 1-31) (FITC)

Go to Product page

Overview

Quantity:	100 µL
Target:	GLP-1
Binding Specificity:	AA 1-31
Reactivity:	Human, Rat, Mouse
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This GLP-1 antibody is conjugated to FITC
Application:	Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details

Immunogen:	KLH conjugated GLP-1 peptide
Isotype:	IgG
Cross-Reactivity:	Human, Mouse, Rat
Purification:	Purified by Protein A.

Target Details

Target:	GLP-1
Alternative Name:	GLP-1 (GLP-1 Products)
Background:	Synonyms: GLP1, GLP2, GRPP, Glucagon, GCG

Target Details

	Background: Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
Gene ID:	2641
UniProt:	P01275

Application Details

Application Notes:	IF(IHC-P) 1:50-200
	IF(IHC-F) 1:50-200
	IF(ICC) 1:50-200

Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	1 μg/μL

Handling

Buffer:	Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Expiry Date:	12 months